Ampio: Ampion reduces all-cause mortality in COVID-19 respiratory distress by nearly 80%
ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) announced positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in patients as a... Read More
Wednesday April 28, 2021
Zynex appoints Donald Gregg VP of sales and operations of monitoring solutions division
ENGLEWOOD -- Zynex, Inc. (Nasdaq: ZYXI) announced it hired Donald Gregg as VP of sales and operations of its monitoring solutions division. Gregg will lead operations, sales, marketing and... Read More
Wednesday April 21, 2021
Research shows Ampion mimics anti-inflammatory effects of steroids but without adverse effects
ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) announced findings of pre-clinical research demonstrating Ampio's lead drug candidate, Ampion, provides some of the same anti-inflammatory... Read More
Tuesday April 20, 2021
Ampio study: Ampion inhibits key inflammatory pathway in COVID-19 and lupus nephritis
ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) announced results of a pre-clinical study demonstrating Ampion inhibits an important pro-inflammatory pathway in the types of immune cells... Read More
Friday April 9, 2021
Innospec's new Trident bunker fuel additive packages to improve flow properties and operability of IMO 2020-compliant ULSFO and VLSFO fuels
ENGLEWOOD -- Innospec Fuel Specialties (IFS), a division of Innospec Inc. (NASDAQ: IOSP), announced the addition of its new Trident bunker fuel additives to the marine and bunker fuel market. ... Read More
Friday April 2, 2021
Ampio Pharmaceuticals details early positive results for inhaled Ampion in COVID-19 distress
ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) revealed preliminary positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in... Read More
Wednesday March 17, 2021
Ampio adds new hospitals in trial for inhalation treatment of COVID-19
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced the addition of two new study sites to further the expansion of its ongoing U.S. Phase I clinical trial for inhalation... Read More
Wednesday February 24, 2021
Paragon 28 adds magnesium based bone void filler to its portfolio
ENGLEWOOD -- Paragon 28, Inc. announced the launch of MgNum Bone Void Filler (BVF). MgNum BVF is designed to fill bony voids and defects that are not intrinsic to the stability of the bone... Read More
Wednesday February 17, 2021
IN Sponsors
Browse
Entrepreneurial by Nature
